1. Home
  2. Companies
  3. NTI
  4. Material Events

Neurotech International (ASX:NTI) — Material Events

ASX:NTI · 13 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 11 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
11
Neurotech Advances NTI164 with Ethics Nod for Pivotal Phase 3 Autism TrialMedium
Neurotech secures ethics approval to start Phase 3 trial of NTI164 for autism spectrum disorder
2 Feb 2026 ·Clinical Trial Approval Announcement ·85
Neurotech Slashes Loss, Advances NTI164 with Key Trials and Funding BoostHigh
Neurotech halves loss, advances NTI164 clinical programs, secures funding and regulatory milestones
26 Feb 2026 ·Appendix 4D Half Year Report ·85
Neurotech Advances NTI164 with Positive Human Data and Strategic US LeadershipMedium
Neurotech reports positive NTI164 clinical and preclinical results, advances regulatory progress, appoints US medical advisor, and focuses on core drug development
31 July 2025 ·Quarterly Activities Report and Appendix 4C ·85
Neurotech Launches NTI164 Prescriber Program Amid FDA Rare Disease NodMedium
Neurotech launches NTI164 prescriber program, gains FDA rare disease designation, advances clinical and regulatory progress
28 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·85
Neurotech Launches Phase 3 Trial Site for Autism Treatment NTI164Medium
Neurotech launches first Phase 3 clinical site for NTI164 autism trial
17 Mar 2026 ·Clinical Trial Update ·85
Neurotech Advances NTI164 with FDA Rare Disease Nod and $8.7M BoostMedium
Neurotech secures FDA Rare Pediatric Disease Designation for NTI164, publishes positive clinical data, and raises $8.7M to advance paediatric neurology programs
30 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·85
Neurotech’s NTI164 Gains FDA Rare Pediatric Disease Designation for Rett SyndromeMedium
Neurotech's NTI164 receives FDA Rare Pediatric Disease Designation for Rett syndrome
8 Oct 2025 ·Regulatory Announcement ·85
Neurotech Advances Phase 3 Autism Trial and Reports Strong Safety Data for NTI164Medium
Neurotech advances Phase 3 autism trial, reports positive safety data and new Rett syndrome collaboration
29 Apr 2026 ·Quarterly Activities Report ·80
Neurotech Secures $4M to Propel Paediatric Neurological Drug TrialsMedium
Neurotech International secures $4M placement to advance paediatric neurological drug development
17 Dec 2025 ·Capital Raising ·80
Neurotech Doubles Loss Amid Clinical Breakthroughs for NTI164Medium
Neurotech reports doubled loss on lower revenues but advances clinical and regulatory milestones for NTI164
29 Aug 2025 ·Preliminary Final Report and Annual Report ·75
Neurotech’s NTI164 Clears Key Safety Hurdle in 90-Day Toxicology StudyMedium
Neurotech's NTI164 shows favorable long-term safety in 90-day GLP toxicology study
23 Feb 2026 ·Clinical Trial Safety Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.